ascopubs.org

Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy.

An international survey of health care providers involved in the management of cancer patients exposed to cardiotoxic therapies. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I.
TCTMD

Event Rates, Effect Sizes Often Overestimated in Major CV Trials

Across contemporary cardiovascular clinical trials, the estimates of expected event rates and effect sizes that investigators use to calculate sample sizes—and funding requirements—often come in ...
ascopubs.org

Combining efficacy and toxicity effect sizes from randomized clinical trials (RCTs) into an interpretable quality-adjusted effect size estimate in patients with multiple ...

Identification of additional therapeutic options for de novo acute myeloid leukemia (AML) patient enabled by next generation sequencing (NGS). This is an ASCO Meeting Abstract from the 2015 ASCO ...